Bdparp 150 mg Tablet

Description

Bdparp 150 mg Tablet contains Olaparib, a targeted anticancer medicine classified as a PARP inhibitor. It is used in the treatment of specific cancers associated with BRCA or homologous recombination repair (HRR) gene mutations. By blocking DNA repair in cancer cells, Bdparp helps slow tumor growth and promotes cancer cell death. Treatment must be taken under specialist supervision.

Benefits

• Targets cancer cells with defective DNA repair

• Helps slow cancer progression

• Improves progression-free survival in eligible patients

• Oral therapy suitable for long-term treatment

• Effective as maintenance therapy in selected cancers

Indications and Usage

Bdparp 150 mg Tablet is indicated for the treatment of:

• Ovarian cancer (BRCA-mutated or HRD-positive)

• Breast cancer (germline BRCA-mutated, HER2-negative)

• Metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations

• Pancreatic cancer with germline BRCA mutation (maintenance therapy)

Use depends on confirmed genetic testing, prior treatment history, and oncologist recommendation.

How it Works

Olaparib inhibits PARP (Poly ADP-Ribose Polymerase) enzymes that cancer cells rely on to repair damaged DNA.
In tumors with BRCA or HRR mutations, PARP inhibition leads to accumulation of DNA damage, resulting in selective cancer cell death while largely sparing normal cells.

Dosage & Administration

• Dosage is determined strictly by the treating oncologist

• Treatment often involves multiple daily doses using 150 mg tablets

• Swallow tablets whole with water

• Take doses at the same time each day

• Food instructions must be followed exactly as prescribed

• Do not crush, chew, or split tablets

• Regular blood count monitoring is required during treatment

Side Effects

Common side effects:

• Fatigue or weakness

• Nausea or vomiting

• Anemia

• Loss of appetite

• Diarrhea

• Headache

Serious side effects (seek immediate medical attention):

• Severe anemia or low blood counts

• Myelodysplastic syndrome (MDS) / Acute Myeloid Leukemia (rare)

• Lung inflammation (pneumonitis)

• Severe or persistent infections

Warning and Precaution

• Not recommended during pregnancy or breastfeeding

• Effective contraception required during treatment and after completion

• Use caution in patients with kidney impairment

• Monitor blood counts regularly due to risk of anemia and cytopenias

• Avoid strong CYP3A inhibitors or inducers unless advised by a doctor

• Report shortness of breath, fever, persistent fatigue, or bleeding immediately